Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Genus PLC, trading under the ticker GNS on the London Stock Exchange, specializes in animal genetics and biotechnology. The company, founded in 1994 and headquartered in Basingstoke, United Kingdom, operates across multiple countries offering genetically superior pig and cattle breeding stock along with state-of-the-art in vitro fertilization products. Genus PLC aims to empower customers in the livestock sector to enhance the efficiency and profitability of their operations by providing innovative genetic solutions and services.
View stock
VS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
View stock

Stock highlights

Stock comparison highlights
Stock name
GenusAbbVie
Last price
£22.38$284.35
Currency
GBP
USD
£1.5B$503B
5.3080.46
£4.25$3.54
0.910.28
£0.33$6.83
1.46%2.43%
Sector
HealthHealth
Employees
2,92157,000
Ticker
£GNS$ABBV
Primary listing
LSENYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in £GNS or $ABBV on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.